Full catalog

The full catalog, with the status on every line.

Search 246 APIs. Every line shows its FDA status as of Nov 14, 2026. Every quote includes the lot COA.

503B Category 1 FDA interim policy, conditions applyCategory 2 FDA safety risk, outside the interim policyBiologic not eligible for 503A/503B compoundingWithdrawn list not for human compoundingNo 503B pathway not on the bulks list, the shortage list or in Category 1503A HHS draft policy formVeterinary animal compounding

Status as of Nov 14, 2026. Sources: FDA 503B categories list (updated Mar 21, 2025), FDA Category 2 page (current Apr 22, 2026), 21 CFR 216.24, 21 CFR 530.41, 21 CFR 600.3(h)(6), HHS FR 2026-22192. No item we list is on the 503B bulks list today. Shortage status is checked when we price your request. Labels are a starting point, not a determination for your facility.

A
Acarbose No 503B pathwayPrice this item
Acetyl Hexapeptide-3 Acetate No 503B pathwayPrice this item
503B Category 3 (nominated without adequate support).
Acitretin No 503B pathwayPrice this item
ACTH 1-24 (Tetracosactide Acetate) No 503B pathwayPrice this item
Adapalene 503B Category 1Price this item
Adenosine 5'-Monophosphate No 503B pathwayPrice this item
Adenosine 5'-Monophosphate Disodium Salt No 503B pathwayPrice this item
Albendazole No 503B pathwayPrice this item
Alpha Lipoic Acid 503B Category 1Price this item
Alprostadil 503B Category 1Price this item
Altrenogest No 503B pathway VeterinaryPrice this item
5-Amino-1-Methylquinolinium Iodide (NNMTi) No 503B pathwayPrice this item
FDA named 5-amino-1MQ as ineligible under 503B in a Jan 2026 warning letter.
Aminocaproic Acid No 503B pathwayPrice this item
4-Aminopyridine No 503B pathwayPrice this item
503B Category 3 (nominated without adequate support).
Amlexanox No 503B pathwayPrice this item
Ammonium Tetrathiomolybdate No 503B pathwayPrice this item
Anamorelin HCl No 503B pathwayPrice this item
Anastrozole 503B Category 1Price this item
AOD-9604 Acetate No 503B pathwayPrice this item
FDA previously listed safety concerns (nomination withdrawn from Category 2).
ARA290 (Cibinetide) Acetate No 503B pathwayPrice this item
Artemisinin No 503B pathwayPrice this item
Atipamezole Hydrochloride No 503B pathway VeterinaryPrice this item
Azaperone No 503B pathway VeterinaryPrice this item
Azelaic Acid 503B Category 1Price this item
Azelastine Hydrochloride No 503B pathwayPrice this item
Azithromycin Dihydrate 503B Category 1Price this item
B
Benazepril Hydrochloride No 503B pathway VeterinaryPrice this item
Benzocaine 503B Category 1Price this item
Bimatoprost 503B Category 1Price this item
BPC-157 Acetate No 503B pathway 503A: HHS draft policyPrice this item
503A: covered by the HHS draft six-peptide policy (Oct 30, 2026) in the acetate form, by the listed routes, if all 10 conditions are met. Draft, nonbinding.
BPC-157 Base No 503B pathwayPrice this item
Outside the HHS 503A draft policy (acetate form only).
Bremelanotide Acetate No 503B pathwayPrice this item
Brimonidine Tartrate 503B Category 1Price this item
Bromfenac Sodium 503B Category 1Price this item
Category 1 entry is for ophthalmic use.
Budesonide Micronized 503B Category 1Price this item
Bupropion Hydrochloride No 503B pathwayPrice this item
Butaphosphan No 503B pathway VeterinaryPrice this item
Butylscopolamine Bromide No 503B pathwayPrice this item
C
Cabergoline No 503B pathwayPrice this item
Calcipotriene Anhydrous 503B Category 1Price this item
Cantharidin 503B Category 1Price this item
Carprofen No 503B pathway VeterinaryPrice this item
CB4211 Acetate No 503B pathwayPrice this item
Not found in FDA’s 503B category list; status to be verified.
Chlorambucil No 503B pathwayPrice this item
Chloramphenicol 503B Category 1 Not for food-producing animalsPrice this item
503B Category 1 except oral use. Oral human products are on FDA's withdrawn list.
Chloramphenicol Palmitate 503B Category 1 Not for food-producing animals VeterinaryPrice this item
503B Category 1 except oral use. Oral human products are on FDA's withdrawn list.
Cholestyramine 503B Category 1Price this item
Cidofovir Anhydrous 503B Category 1Price this item
Cidofovir Dihydrate 503B Category 1Price this item
Cimetidine 503B Category 1Price this item
CJC-1295 Acetate No 503B pathwayPrice this item
FDA previously listed safety concerns (nomination withdrawn from Category 2).
Clascoterone No 503B pathwayPrice this item
Clenbuterol Hydrochloride No 503B pathway Not for food-producing animals VeterinaryPrice this item
Not approved for human use in the US.
Clomiphene Citrate No 503B pathwayPrice this item
Clopidogrel Bisulfate No 503B pathwayPrice this item
Cromolyn Sodium 503B Category 1Price this item
Curcumin 99% No 503B pathwayPrice this item
Cyclophosphamide Monohydrate No 503B pathwayPrice this item
Cyclosporine A 503B Category 1Price this item
D
D-Biotin 503B Category 1Price this item
D-Penicillamine No 503B pathwayPrice this item
Danazol No 503B pathwayPrice this item
Dantrolene Sodium No 503B pathwayPrice this item
Dapsone 503B Category 1Price this item
Dasatinib Monohydrate No 503B pathwayPrice this item
Decoquinate No 503B pathway VeterinaryPrice this item
Delta Sleep Inducing Peptide (DSIP) Acetate No 503B pathwayPrice this item
FDA previously listed safety concerns (nomination withdrawn from Category 2).
Demecarium Bromide No 503B pathway VeterinaryPrice this item
2-Deoxy-D-Glucose 503B Category 1Price this item
Deslorelin Acetate No 503B pathway VeterinaryPrice this item
Desmopressin Acetate Trihydrate No 503B pathwayPrice this item
Detomidine Hydrochloride No 503B pathway VeterinaryPrice this item
Diazoxide No 503B pathwayPrice this item
Diclazuril No 503B pathway VeterinaryPrice this item
Diclofenac Sodium 503B Category 1Price this item
Dihexa Acetate No 503B pathwayPrice this item
FDA previously listed safety concerns (nomination withdrawn from Category 2).
Diindolylmethane No 503B pathwayPrice this item
DMPS (Sodium 2,3-Dimercaptopropanesulfonate Monohydrate) No 503B pathwayPrice this item
DMSA (2,3-Dimercaptosuccinic Acid) No 503B pathwayPrice this item
503B Category 3 (nominated without adequate support).
Dutasteride 503B Category 1Price this item
E
Eflornithine Hydrochloride Monohydrate 503B Category 1Price this item
Enalapril Maleate 503B Category 1Price this item
Enclomiphene Citrate No 503B pathwayPrice this item
Enrofloxacin No 503B pathway VeterinaryPrice this item
Epithalon Acetate No 503B pathway 503A: HHS draft policyPrice this item
503A: covered by the HHS draft six-peptide policy (Oct 30, 2026) in the acetate form, by the listed routes, if all 10 conditions are met. Draft, nonbinding.
Estradiol Cypionate 503B Category 1Price this item
Estradiol Hemihydrate (Micronized) 503B Category 1Price this item
Estriol (Micronized) 503B Category 1Price this item
Estrone 503B Category 1Price this item
F
Famciclovir No 503B pathwayPrice this item
Finasteride 503B Category 1Price this item
Firocoxib No 503B pathway VeterinaryPrice this item
5-Fluorouracil 503B Category 1Price this item
FOXO-4 DRI Acetate No 503B pathwayPrice this item
Furosemide 503B Category 1Price this item
G
Gabapentin 503B Category 1Price this item
Controlled in some states; flagged by ship-to state.
Gatifloxacin Sesquihydrate 503B Category 1Price this item
Category 1 entry is for ophthalmic solutions.
GHK Acetate No 503B pathwayPrice this item
GHK-Cu Acetate No 503B pathwayPrice this item
GHRP-2 Acetate 503B Category 2: FDA safety riskPrice this item
Category 2 for injectable and nasal use; Category 1 for other routes.
Gonadorelin Acetate 503B Category 1Price this item
Griseofulvin No 503B pathwayPrice this item
Guanabenz Acetate No 503B pathwayPrice this item
H
Hexarelin Acetate No 503B pathwayPrice this item
Histrelin Acetate No 503B pathwayPrice this item
Humanin Acetate No 503B pathwayPrice this item
Hyaluronic Acid Sodium Salt 503B Category 1Price this item
Hydroxypropyl Beta Cyclodextrin No 503B pathwayPrice this item
Hydroxypropyl Gamma Cyclodextrin No 503B pathwayPrice this item
Hydroxyurea No 503B pathwayPrice this item
I
Imatinib Mesylate (Crystal Form Alpha) 503B Category 1Price this item
Imiquimod 503B Category 1Price this item
iRGD Acetate No 503B pathwayPrice this item
Iron Sucrose No 503B pathwayPrice this item
Isoflupredone Acetate No 503B pathway VeterinaryPrice this item
Isoniazid No 503B pathwayPrice this item
Itraconazole 503B Category 1Price this item
Ivermectin 503B Category 1Price this item
K
KCF-18 Acetate No 503B pathwayPrice this item
Ketotifen Fumarate No 503B pathwayPrice this item
503B Category 3 (nominated without adequate support).
Kisspeptin-10 Acetate No 503B pathwayPrice this item
503A: Category 2 (FDA safety risk).
Kojic Acid No 503B pathwayPrice this item
503B Category 3 (nominated without adequate support).
KPV Acetate No 503B pathway 503A: HHS draft policyPrice this item
503A: covered by the HHS draft six-peptide policy (Oct 30, 2026) in the acetate form, by the listed routes, if all 10 conditions are met. Draft, nonbinding.
L
L-5-Methyltetrahydrofolate Calcium 503B Category 1Price this item
L-Asparaginase Biologic: not compoundablePrice this item
L-Glutathione (Reduced) 503B Category 1Price this item
L-Tryptophan No 503B pathwayPrice this item
503B Category 3 (nominated without adequate support).
Lansoprazole 503B Category 1Price this item
Latanoprost 503B Category 1Price this item
Leflunomide No 503B pathwayPrice this item
Leucovorin Calcium No 503B pathwayPrice this item
Leuprolide Acetate No 503B pathwayPrice this item
Levamisole Hydrochloride No 503B pathway VeterinaryPrice this item
Levetiracetam No 503B pathwayPrice this item
Levofloxacin Hemihydrate No 503B pathwayPrice this item
Lidocaine (Base) 503B Category 1Price this item
Liraglutide No 503B pathwayPrice this item
No current 503B bulk pathway. Off the shortage list (tirzepatide Dec 19, 2024; semaglutide Feb 21, 2025). FDA proposed May 1, 2026 not to add it to the 503B bulks list. Manufacturer must be on FDA Import Alert 66-80 Green List.
LL-37 Acetate No 503B pathwayPrice this item
FDA previously listed safety concerns (nomination withdrawn from Category 2).
Lovastatin No 503B pathwayPrice this item
M
Marbofloxacin No 503B pathway VeterinaryPrice this item
Maropitant Citrate No 503B pathway VeterinaryPrice this item
Mebendazole No 503B pathwayPrice this item
Medetomidine Hydrochloride No 503B pathway VeterinaryPrice this item
Megestrol Acetate No 503B pathwayPrice this item
Melanotan I Acetate No 503B pathwayPrice this item
Melanotan II Acetate No 503B pathwayPrice this item
FDA previously listed safety concerns (nomination withdrawn from Category 2).
Melphalan No 503B pathwayPrice this item
Met-Enkephalin Acetate No 503B pathwayPrice this item
Methazolamide No 503B pathwayPrice this item
Methylcobalamin (Mecobalamin) 503B Category 1Price this item
Methylene Blue No 503B pathwayPrice this item
Not found in FDA’s 503B category list; status to be verified.
5-Methyltetrahydrofolic Acid (Methyl Folate) No 503B pathwayPrice this item
Metronidazole Benzoate No 503B pathway Not for food-producing animals VeterinaryPrice this item
Minocycline Hydrochoride 503B Category 1Price this item
Minoxidil 503B Category 1Price this item
Mirtazapine Anhydrous No 503B pathwayPrice this item
Mitomycin 503B Category 1Price this item
Mitotane No 503B pathwayPrice this item
Molnupiravir No 503B pathwayPrice this item
Monobenzone No 503B pathwayPrice this item
MOTs-C Acetate No 503B pathway 503A: HHS draft policyPrice this item
503A: covered by the HHS draft six-peptide policy (Oct 30, 2026) in the acetate form, by the listed routes, if all 10 conditions are met. Draft, nonbinding.
Moxifloxacin Hydrochloride 503B Category 1Price this item
α-MSH (Alpha-Melanocyte-Stimulating Hormone) No 503B pathwayPrice this item
Mycophenolate Mofetil No 503B pathwayPrice this item
N
N-Acetyl-BPC-Amidate No 503B pathwayPrice this item
Outside the HHS 503A draft policy (acetate form only).
Naltrexone Hydrochloride (Anhydrous) 503B Category 1Price this item
Niclosamide Anhydrous No 503B pathwayPrice this item
β-Nicotinamide Adenine Dinucleotide (β-NAD+) 503B Category 1Price this item
FDA's Jan 20, 2026 warning letter to an outsourcing facility treated NAD+ as ineligible under 503B. The disodium salt trihydrate form is Category 3. Exact form stated on the quote.
β-Nicotinamide Mononucleotide (NMN) No 503B pathwayPrice this item
Not found in FDA’s 503B category list; status to be verified.
Nifedipine 503B Category 1Price this item
Nitazoxanide No 503B pathwayPrice this item
Nitrofurantoin Anhydrous No 503B pathway Not for food-producing animalsPrice this item
O
Orlistat No 503B pathwayPrice this item
Oxymetazoline Hydrochloride 503B Category 1Price this item
Oxytocin 503B Category 1Price this item
P
P-21 Acetate No 503B pathwayPrice this item
Papaverine Hydrochloride 503B Category 1Price this item
PE 22-28 Acetate No 503B pathwayPrice this item
PEG-MGF Acetate No 503B pathwayPrice this item
FDA previously listed safety concerns (nomination withdrawn from Category 2).
Pentadecapeptide Arginate (BPC-157 Arginate) No 503B pathwayPrice this item
Outside the HHS 503A draft policy (acetate form only).
Pentosan Polysulfate Sodium No 503B pathwayPrice this item
Phenoxybenzamine Hydrochloride 503B Category 1Price this item
Phentolamine Mesylate 503B Category 1Price this item
Pimobendan No 503B pathway VeterinaryPrice this item
503B Category 3 (nominated without adequate support).
Pinealon Acetate No 503B pathwayPrice this item
Ponazuril No 503B pathway VeterinaryPrice this item
Potassium Bromide 503B Category 1 VeterinaryPrice this item
Praziquantel No 503B pathway VeterinaryPrice this item
Prazosin Hydrochloride No 503B pathwayPrice this item
Prilocaine Hydrochloride 503B Category 1Price this item
Procaine Hydrochloride 503B Category 1Price this item
Procarbazine Hydrochloride No 503B pathwayPrice this item
Progesterone (Micronized) 503B Category 1Price this item
Protirelin Acetate No 503B pathwayPrice this item
503B Category 3 (nominated without adequate support).
PTD-DBM Acetate No 503B pathwayPrice this item
Pyrantel Pamoate No 503B pathway VeterinaryPrice this item
503B Category 3 (nominated without adequate support).
Pyrazinamide No 503B pathwayPrice this item
Pyridostigmine Bromide No 503B pathwayPrice this item
Pyrimethamine No 503B pathwayPrice this item
R
(6R)-5,6,7,8-Tetrahydro-L-Biopterin Dihydrochloride No 503B pathwayPrice this item
Reserpine No 503B pathwayPrice this item
Resveratrol No 503B pathwayPrice this item
503B Category 3 (nominated without adequate support).
Rifampin (Rifampicin) No 503B pathwayPrice this item
Romifidine Hydrochloride No 503B pathway VeterinaryPrice this item
Ronidazole No 503B pathway Not for food-producing animals VeterinaryPrice this item
Rusalatide (TP508) Acetate No 503B pathwayPrice this item
S
Salcaprozate Sodium (SNAC) No 503B pathwayPrice this item
Secnidazole No 503B pathwayPrice this item
Selank Acetate No 503B pathwayPrice this item
FDA previously listed safety concerns (nomination withdrawn from Category 2).
Semaglutide No 503B pathwayPrice this item
No current 503B bulk pathway. Off the shortage list (tirzepatide Dec 19, 2024; semaglutide Feb 21, 2025). FDA proposed May 1, 2026 not to add it to the 503B bulks list. Manufacturer must be on FDA Import Alert 66-80 Green List. Base form only. FDA says the salt forms have no lawful basis for compounding.
Semax Acetate No 503B pathwayPrice this item
HHS draft 503A policy lists Semax free base (intranasal), not the acetate.
Sermorelin Acetate 503B Category 1Price this item
Setmelanotide Acetate No 503B pathwayPrice this item
Sildenafil Citrate 503B Category 1Price this item
Sirolimus (Rapamycin) No 503B pathwayPrice this item
SLU-PP-332 No 503B pathwayPrice this item
Not found in FDA’s 503B category list; status to be verified.
Sodium Phenylbutyrate No 503B pathwayPrice this item
Sulpiride No 503B pathwayPrice this item
T
Tacrolimus Monohydrate 503B Category 1Price this item
Tadalafil 503B Category 1Price this item
Taurine 503B Category 1Price this item
Telmisartan No 503B pathwayPrice this item
Terbinafine Hydrochloride 503B Category 1Price this item
Tesamorelin Acetate No 503B pathwayPrice this item
44 amino acids; biologic status unverified.
Thymosin Alpha-1 Acetate No 503B pathwayPrice this item
503B Category 3 (nominated without adequate support). Also on the withdrawn-from-Category-2 list.
Thymosin Beta-4 Acetate Biologic: not compoundablePrice this item
Treated as a likely biologic (protein over 40 amino acids); FDA has not ruled on this item.
Thymosin Beta-4 Fragment (TB500) Acetate No 503B pathway 503A: HHS draft policyPrice this item
503A: covered by the HHS draft six-peptide policy (Oct 30, 2026) in the acetate form, by the listed routes, if all 10 conditions are met. Draft, nonbinding.
Thymulin Acetate No 503B pathwayPrice this item
Tirzepatide No 503B pathwayPrice this item
No current 503B bulk pathway. Off the shortage list (tirzepatide Dec 19, 2024; semaglutide Feb 21, 2025). FDA proposed May 1, 2026 not to add it to the 503B bulks list. Manufacturer must be on FDA Import Alert 66-80 Green List.
Toceranib Phosphate No 503B pathway VeterinaryPrice this item
Tofacitinib Citrate 503B Category 1Price this item
Tolazoline Hydrochloride No 503B pathwayPrice this item
Toltrazuril No 503B pathway VeterinaryPrice this item
503B Category 3 (nominated without adequate support).
Topiramate 503B Category 1Price this item
Tranexamic Acid 503B Category 1Price this item
Trazodone Hydrochloride No 503B pathwayPrice this item
Tretinoin 503B Category 1Price this item
Trilostane No 503B pathway VeterinaryPrice this item
503B Category 3 (nominated without adequate support).
Tylosin Tartrate No 503B pathway VeterinaryPrice this item
U
Ursodeoxycholic Acid (Ursodiol) No 503B pathwayPrice this item
V
Vancomycin Hydrochloride 503B Category 1Price this item
Vardenafil Hydrochloride Trihydrate 503B Category 1Price this item
Vasoactive Intestinal Peptide (VIP) Acetate No 503B pathwayPrice this item
Voriconazole No 503B pathwayPrice this item
Y
Yohimbine Hydrochloride No 503B pathwayPrice this item
Z
Zonisamide No 503B pathwayPrice this item

Not listed? Send the name and spec. We source it and price it on the same sheet. We don't source substances FDA has said can't lawfully be compounded.

Price-check one item